KPTI Karyopharm Therapeutics Inc.
Debt Financing ·
Lenders and noteholders agreed to forbear from enforcing remedies for a limited period. The forbearance period is set to end October 15, 2026 unless extended, and can end sooner on several triggers.
Karyopharm closed a recapitalization on October 10, 2025 that borrowed $12.5 million under its term loan, issued $15.0 million of 9.00% notes due 2028 and $103.5 million of 9.00% notes due 2029, and exchanged $100.978 million of older notes. Lenders also waived specified defaults under the loan.
The deals combine new loans and notes, payment deferrals, debt-for-equity exchanges and a private placement of about $8.75 million. Karyopharm expects about $36 million of gross proceeds and a cash runway into the second quarter of 2026.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $146.1 million | $145.2 million |
| Research and development | $125.6 million | $143.2 million |
| Net income (loss) | -$196.0 million | -$76.4 million |
| Cash from operations | -$75.4 million | -$127.5 million |
| Cash and equivalents | $60.5 million | $62.5 million |
| Short-term investments | $3.2 million | $46.2 million |
Our latest story on this, dated Oct 8, 2025: "Karyopharm agrees debt and equity deals it says give $100 million of flexibility". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 14, 2025: "Karyopharm closes recapitalization with 9.00% convertible notes and $12.5 million loan draw". The story links the filing or release it is based on. Read the story.
Karyopharm Therapeutics Inc. trades under the ticker KPTI on NASDAQ.
Karyopharm Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:25K0; LS:A40YLC; LSX:A40YLC.
The SEC Central Index Key (CIK) for Karyopharm Therapeutics Inc. is 1503802. Its filings are on SEC EDGAR.
22,681,460 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Karyopharm Therapeutics Inc. under United States.
Our directory classifies Karyopharm Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Karyopharm Therapeutics Inc. is US48576U2050.
aibio.space lists Karyopharm Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$146.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Karyopharm Therapeutics Inc. reported a net loss of $196.0 million for the fiscal year ended Dec 31, 2025, and used $75.4 million of cash in operations, per its annual report to the SEC.
$125.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
$65.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported that a debt obligation was accelerated. SEC Form 8-K (Items 1.01,2.04,3.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,2.03,3.02,5.02,7.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio